MAD1L1 Variant 3: A Promising Target for Small Molecules and Biomarkers

Target Name: MAD1L1

NCBI ID: G8379

MAD1L1

MAD1L1 Variant 3: A Promising Target for Small Molecules and Biomarkers

MAD1L1 (MAD1L1 variant 3) is a protein that is expressed in various tissues throughout the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the MAD1L1 gene family, which is known for its role in regulating cell signaling pathways.

MAD1L1 variant 3 is a unique isoform of the MAD1L1 gene that has been shown to have distinct functions compared to the other isoforms. One of the main differences between MAD1L1 variant 3 and the other isoforms is its stability. MAD1L1 variant 3 is more stable than the other isoforms, which means it is more likely to be expressed in cells for a longer period of time.

Another difference between MAD1L1 variant 3 and the other isoforms is its processing. MAD1L1 variant 3 is processed differently than the other isoforms, which means it is not as easily accessible to small molecules that can interact with its signaling domains. This may make it more resistant to drug intervention.

MAD1L1 variant 3 is also known for its role in the regulation of cellular signaling pathways. It has been shown to play a role in the regulation of cell proliferation, differentiation, and survival. MAD1L1 variant 3 has also been shown to interact with various signaling molecules, including TGF-β, PDGF, and NF-kappa-B.

In addition to its role in cellular signaling pathways, MAD1L1 variant 3 is also being investigated as a potential drug target. Several studies have shown that MAD1L1 variant 3 can be targeted by small molecules, including inhibitors of the tyrosine kinase activity of MAD1L1 variant 3. These inhibitors have been shown to reduce the activity of MAD1L1 variant 3 and its downstream signaling pathways.

Furthermore, MAD1L1 variant 3 has also been shown to be a potential biomarker for certain diseases. For example, MAD1L1 variant 3 has been shown to be overexpressed in certain types of cancer, such as lung cancer and breast cancer. This may make it a useful biomarker for these diseases.

In conclusion, MAD1L1 variant 3 is a unique protein that has distinct functions compared to the other isoforms of the MAD1L1 gene. Its stability and processing differences, as well as its role in cellular signaling pathways, make it a promising target for small molecules. Furthermore, MAD1L1 variant 3 has also been shown to be a potential biomarker for certain diseases, which may make it an important tool for the development of new treatments.

Protein Name: Mitotic Arrest Deficient 1 Like 1

Functions: Component of the spindle-assembly checkpoint that prevents the onset of anaphase until all chromosomes are properly aligned at the metaphase plate (PubMed:10049595, PubMed:20133940, PubMed:29162720). Forms a heterotetrameric complex with the closed conformation form of MAD2L1 (C-MAD2) at unattached kinetochores during prometaphase, recruits an open conformation of MAD2L1 (O-MAD2) and promotes the conversion of O-MAD2 to C-MAD2, which ensures mitotic checkpoint signaling (PubMed:29162720)

The "MAD1L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAD1L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets